The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy that has been the standard treatment for years. The approval has the potential to improve access to treatment and outcomes, but many challenges remain in implementing trial findings into clinical practice.
